These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 18454322)

  • 1. Indolealkylamines: biotransformations and potential drug-drug interactions.
    Yu AM
    AAPS J; 2008 Jun; 10(2):242-53. PubMed ID: 18454322
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinically significant drug interactions with agents specific for migraine attacks.
    Eadie MJ
    CNS Drugs; 2001; 15(2):105-18. PubMed ID: 11460889
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Psychedelic 5-methoxy-N,N-dimethyltryptamine: metabolism, pharmacokinetics, drug interactions, and pharmacological actions.
    Shen HW; Jiang XL; Winter JC; Yu AM
    Curr Drug Metab; 2010 Oct; 11(8):659-66. PubMed ID: 20942780
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Review: Pharmacogenetic aspects of the effect of cytochrome P450 polymorphisms on serotonergic drug metabolism, response, interactions, and adverse effects.
    Pilgrim JL; Gerostamoulos D; Drummer OH
    Forensic Sci Med Pathol; 2011 Jun; 7(2):162-84. PubMed ID: 21052868
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Direct-acting antiviral interactions with opioids, alcohol or illicit drugs of abuse in HCV-infected patients.
    Ing Lorenzini K; Girardin F
    Liver Int; 2020 Jan; 40(1):32-44. PubMed ID: 31654604
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Triptans (serotonin, 5-HT1B/1D agonists) in migraine: detailed results and methods of a meta-analysis of 53 trials.
    Ferrari MD; Goadsby PJ; Roon KI; Lipton RB
    Cephalalgia; 2002 Oct; 22(8):633-58. PubMed ID: 12383060
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Choosing the safest acute therapy during chronic migraine prophylactic treatment: pharmacokinetic and pharmacodynamic considerations.
    Lionetto L; Borro M; Curto M; Capi M; Negro A; Cipolla F; Gentile G; Martelletti P
    Expert Opin Drug Metab Toxicol; 2016; 12(4):399-406. PubMed ID: 26878379
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Present and future of 5-HT receptor agonists as antimigraine drugs.
    Pauwels PJ; John GW
    Clin Neuropharmacol; 1999; 22(3):123-36. PubMed ID: 10367177
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Developments in 5-hydroxytryptamine receptor pharmacology in migraine.
    Peroutka SJ
    Neurol Clin; 1990 Nov; 8(4):829-39. PubMed ID: 2259314
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Polymorphic cytochrome P450 2D6: humanized mouse model and endogenous substrates.
    Yu AM; Idle JR; Gonzalez FJ
    Drug Metab Rev; 2004 May; 36(2):243-77. PubMed ID: 15237854
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adverse pharmacokinetic interactions between illicit substances and clinical drugs.
    Abbott KL; Flannery PC; Gill KS; Boothe DM; Dhanasekaran M; Mani S; Pondugula SR
    Drug Metab Rev; 2020 Feb; 52(1):44-65. PubMed ID: 31826670
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination of NSAID and Triptan in Migraine Treatment and Cardiovascular Risk: Is It Safe?
    Maggioni F; Terrin A; Maggioni G; Mainardi F
    Headache; 2017 Nov; 57(10):1622-1623. PubMed ID: 29124758
    [No Abstract]   [Full Text] [Related]  

  • 13. Methysergide.
    Silberstein SD
    Cephalalgia; 1998 Sep; 18(7):421-35. PubMed ID: 9793694
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Drug-Drug Interactions in Headache Medicine.
    Ansari H; Ziad S
    Headache; 2016 Jul; 56(7):1241-8. PubMed ID: 27350319
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dose-Response Pharmacological Study of Mephedrone and Its Metabolites: Pharmacokinetics, Serotoninergic Effects, and Impact of CYP2D6 Genetic Variation.
    Olesti E; Farré M; Carbó ML; Papaseit E; Perez-Mañá C; Torrens M; Yubero-Lahoz S; Pujadas M; Pozo ÓJ; de la Torre R
    Clin Pharmacol Ther; 2019 Sep; 106(3):596-604. PubMed ID: 30815856
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CYP2D6 genetic polymorphisms and their relevance for poisoning due to amfetamines, opioid analgesics and antidepressants.
    Haufroid V; Hantson P
    Clin Toxicol (Phila); 2015 Jul; 53(6):501-10. PubMed ID: 25998998
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative Analysis of Hydrophilic Ingredients in Toad Skin and Toad Venom Using the UHPLC-HR-MS/MS and UPLC-QqQ-MS/MS Methods Together with the Anti-Inflammatory Evaluation of Indolealkylamines.
    Zhang Y; Yuan B; Takagi N; Wang H; Zhou Y; Si N; Yang J; Wei X; Zhao H; Bian B
    Molecules; 2018 Dec; 24(1):. PubMed ID: 30591646
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of monoamine oxidase inhibitor and cytochrome P450 2D6 status on 5-methoxy-N,N-dimethyltryptamine metabolism and pharmacokinetics.
    Shen HW; Wu C; Jiang XL; Yu AM
    Biochem Pharmacol; 2010 Jul; 80(1):122-8. PubMed ID: 20206139
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Clinical use of triptans in the management of migraine].
    Lantéri-Minet M
    CNS Drugs; 2006; 20 Spec no.1():12-23. PubMed ID: 16841523
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Is toxicity of PMMA (paramethoxymethamphetamine) associated with cytochrome P450 pharmacogenetics?
    Vevelstad M; Øiestad EL; Bremer S; Bogen IL; Zackrisson AL; Arnestad M
    Forensic Sci Int; 2016 Apr; 261():137-47. PubMed ID: 26930544
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.